Last reviewed · How we verify
TAZOBACTAM SODIUM
At a glance
| Generic name | TAZOBACTAM SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
Common side effects
- Diarrhea
- Constipation
- Nausea
- Headache
- Insomnia
- Fever
- Rash
- Pruritus
- Candidiasis
- Vomiting
- Dyspepsia
- Abdominal pain
Key clinical trials
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation (PHASE4)
- A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia (NA)
- Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
- Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis (PHASE4)
- Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis. (PHASE4)
- Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group (PHASE4)
- Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAZOBACTAM SODIUM CI brief — competitive landscape report
- TAZOBACTAM SODIUM updates RSS · CI watch RSS